![conference banner](/images/conference-banner.jpeg)
Abstract
Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Current Pharmaceutical Design
Title:Brain Targeting of siRNA via Intranasal Pathway
Volume: 21 Issue: 31
Author(s): Chandana Mohanty, Paromita Kundu and Sanjeeb K. Sahoo
Affiliation:
Keywords: siRNA, brain diseases, intranasal delivery, brain targeting, nanotechnology, delivery vehicles.
Abstract: Brain diseases are the most serious health problems; represent a significant and worldwide public health problem. Small interfering RNAs (siRNAs) can initiate specific silencing of genes and are potential therapeutic agents for many genetically influenced diseases including brain disease. However, on systemic administration the blood-brain barrier (BBB) poses most significant obstacle for the therapeutic siRNAs delivery to the brain. Therefore, the development of successful approaches to enhance siRNA delivery to the brain is of immense interest in clinical and pharmaceutical research. At present, intranasal delivery approach serves as an effective mode of direct delivery of siRNAs to brain by bypassing BBB. In this review, we describe the principles of RNA interference (RNAi) machinery; challenges associated with siRNAs in therapeutics brain targeting and summarize the recent progress made in the use of vector based siRNA technology. Further, it is anticipated that intranasal delivery approach will have a very important role to play in the future for the translation of siRNAs therapeutics from bench to bedside for different brain diseases.
Export Options
About this article
Cite this article as:
Mohanty Chandana, Kundu Paromita and Sahoo K. Sanjeeb, Brain Targeting of siRNA via Intranasal Pathway, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013191737
DOI https://dx.doi.org/10.2174/138161282131151013191737 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Metabolic Basis of Polycystic Ovarian Syndrome; Indications for Biochemical Screening
Endocrine, Metabolic & Immune Disorders - Drug Targets Tales of Biomaterials, Molecules, and Cells for Repairing and Treating Brain Dysfunction
Current Stem Cell Research & Therapy Progression of Alzheimer-type Neurofibrillary Tangles is Related to the Proximodistal Segments of the Hemispheric Arteries
Current Alzheimer Research Cerebrospinal Fluid, Brain Electrolytes Balance, and the Unsuspected Intrinsic Property of Melanin to Dissociate the Water Molecule
CNS & Neurological Disorders - Drug Targets Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Silent Cerebral Damage in Hypertension
Current Hypertension Reviews Carbon Monoxide as a Therapeutic for Airway Diseases: Contrast and Comparison of Various CO Delivery Modalities
Current Topics in Medicinal Chemistry Design and Development of Glutathione Conjugated Poly (d, l) lactide Nanocarriers for Delivery of Hydrophilic Fluorescent Marker across Blood Brain Barrier
Current Nanoscience Secretoneurin: A New Player in Angiogenesis and Chemotaxis Linking Nerves, Blood Vessels and the Immune System
Current Protein & Peptide Science Challenges in Diagnosing Cerebral Lacunar Infarcts
Current Medical Imaging Therapeutic Perspectives for cN-II in Cancer.
Current Medicinal Chemistry Recent Trends in the Management of Alzheimer’s Disease: Current Therapeutic Options and Drug Repurposing Approaches
Current Neuropharmacology Role of <i>Rosmarinus officinalis</i> Aqueous Extract in Relieving the Complications Associated with Ethylene Glycol-induced Urolithiasis in Male Rats
Current Bioactive Compounds Neuropeptide Receptors in Intestinal Disease: Physiology and Therapeutic Potential
Current Pharmaceutical Design True or False? Activations of Language-related Areas in Patients with Disorders of Consciousness
Current Pharmaceutical Design Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Novel Approaches to Study the Involvement of α7-nAChR in Human Diseases
Current Drug Targets